Takeda links with CellCentric on epigenetic target
This article was originally published in Scrip
Executive Summary
Takedahas signed an agreement with CellCentric for the validation of a cancer-related protein identified by the UK firm as a possible therapeutic target. Takeda also has an option to acquire rights to the inhibitor development programme related to the target. CellCentric has a network of relationships with facilities conducting research into epigenetic disease mechanisms, through which it identifies targets for the generation of novel small-molecule drugs. Its investors include the Rainbow Seed Fund, which is funded by the UK Office of Science and Innovation to support the commercialisation of public research.